Swiss biotech AC Immune (Nasdaq: ACIU) has made progress on two fronts with a vaccine that could have massive market value in the neurodegenerative diseases space.
The firm has announced two clinical milestone events related to ACI-24, its vaccine against Alzheimer's disease and amyloid beta-related cognitive decline in Down Syndrome.
AC Immune has started the Phase II study with patients with mild Alzheimer's disease, while it has completed recruitment for the high-dose cohort of a Phase Ib study for the treatment of Alzheimer's disease-like characteristics in adults with Down syndrome.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze